drugset / Trial / NCT02730130
Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients
Phase 2
Completed
17 enrolled
Memorial Sloan Kettering Cancer Center
Cedars-Sinai Medical Center · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on the patient and areas of cancer in their body that did not receive radiation therapy.
Timeline
- Start
- 2016-06-03
- Primary completion
- 2017-09-26
- Completion
- 2022-10-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |